Poonam S Sonawane

Title: Innovator Spotlight: Poonam S Sonawane

Introduction: Poonam S Sonawane, hailing from Winston-Salem, NC, has made significant contributions to the field of cancer research and targeted therapies. With a focus on innovative constructs that enhance therapeutic efficacy, she has been instrumental in developing technologies that hold promise for cancer treatment.

Latest Patents: Poonam S Sonawane holds three patents, with her latest work centering on "EPHA3 and multi-valent targeting of tumors." This invention involves a construct that comprises a binding ligand for EphA3, EphA2, and/or EphB2, along with at least one effector molecule. The effector molecule in some embodiments includes therapeutic agents, nanoparticles, detectable groups, lipids, or liposomes. Additionally, some constructs are designed as fusion proteins or covalent conjugates. Another aspect of her patents includes methods utilizing a ligand that binds to EphA2, EphA3, or EphB2, coupled with a ligand that attaches to IL-13Rα2, for effective cancer treatment.

Career Highlights: Poonam S Sonawane is associated with Wake Forest University, where her research centers around innovative cancer treatments and the development of multi-valent targeting strategies to enhance therapeutic outcomes.

Collaborations: Throughout her career, Poonam has collaborated with esteemed colleagues, including Waldemar Debinski and Carla Lema Tome, contributing to a dynamic research environment focused on cutting-edge cancer therapies.

Conclusion: Poonam S Sonawane exemplifies innovation in cancer treatment through her patents and collaborative efforts at Wake Forest University. Her work is paving the way for advancements in targeted therapies, illustrating the impact of combining inventive constructs with therapeutic applications in the fight against cancer.